Amgen and Kyowa Kirin have shared promising results from a phase 3 programme of their investigational T-cell rebalancing ...
In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...
Analysts were pleasantly surprised by the positive phase III data reported for Kyowa Kirin Co. Ltd./Amgen Inc.’s rocatinlimab, a T-cell rebalancing therapy, in moderate to severe atopic dermatitis.
All the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.
Amgen (AMGN) and Kyowa Kirin (KYKOF) announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an ...
Amgen & Kyowa Kirin positive results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis: Thousand Oaks, California Tuesday, March 11, 2025, ...
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
US biotech Amgen (Nasdaq: AMGN) and Japanese partner Kyowa Kirin (TYO: 4151) announced new results from the ongoing ROCKET ...
Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...
Zacks Investment Research on MSN2d
AMGN's Eczema Drug Meets Goal in Two Late-Stage StudiesAmgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET ...
THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback